Phase 2 noncomparative RCT in 87 cisplatin-ineligible patients with FGFR-altered metastatic urothelial cancer: confirmed ORR was 44.2% with first-line erdafitinib and 54.5% with erdafitinib plus cetrelimab; grade 3 or higher treatment-related AEs 46.5% and 45.5%.
RCTn = 87
Loriot et al. Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study